ReviewMolecular medicine reports2026
Synovial chondromatosis: Novel advances in understanding the pathogenesis and in diagnostic strategies (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The concurrence of osteochondromatosis and bone infarction in a patient with anterior cruciate ligament rupture: a rare case report.International journal of surgery case reports · 2026Article
- Synovial Chondromatosis: A Narrative Review of Current Evidence on Diagnosis, Differential Diagnosis, and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Understanding Synovial Chondromatosis: A Rare Cause of Shoulder Impingement.Journal of orthopaedic case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial chondromatosis (SC) is a relatively rare benign synovial disorder characterized by the abnormal chondroid metaplasia of synovial cells, leading to the formation of multiple cartilage nodules that affect both intra‑articular and extra‑articular synovial tissues. Although the pathogenesis of SC remains incompletely understood, various signaling pathways, the inflammatory microenvironment and mechanical stress carry out key roles in the progression of the disease. Given the advancements in imaging techniques and the pathological mechanisms at play, early diagnosis and lesion evaluation of SC have markedly improved. In terms of treatment, both arthroscopic and open surgeries remain the primary approaches, with total synovectomy is the preferred method given the reduction in recurrence rates. The exploration of biologic agents offers novel possibilities for non‑surgical management. Despite the generally benign nature of SC, recurrent occurrences and the potential for malignant transformation require careful monitoring. Future research should focus on molecular‑targeted therapies, early detection and precision therapeutics to optimize clinical management and long‑term outcomes of patients with SC. The present review discusses the pathogenesis, diagnostic methods, treatment strategies and future research directions of SC, aiming to provide a comprehensive theoretical framework for its clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.